Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Status:
COMPLETED
Trial end date:
2019-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy.
All subjects still in follow-up for the VMDN-003 study or who have completed the Day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.